You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Roche said the timeline to launch a diagnostic system and assays based on PacBio's technology would be too long; instead, it will focus on commercializing Genia's technology.
In October, Roche reported the tissue diagnostics business contributed 8 percent to diagnostics sales in the first nine months of 2016.
The two companies struck a $75 million deal in 2013 to launch a sequencing system and assays for the diagnostic market.
Under the agreement, Roche Diagnostics will offer Good Start's GeneVu carrier screening test along with its Harmony NIPT.
The agreement now includes distribution of Roche's Kapa Biosystems portfolio in all geographies except the US, Brazil, and Japan.
The new assays — one targeting 17 genes and one targeting 77 genes — are based on the CAPP-Seq technology developed by Stanford University
The assay, which was initially approved in June 2015, can now be used on an automated slide stainer which the company said is used in labs all over the world.
The company reported $29.4 million in revenues for the quarter and a net loss of $31.3 million, while the number of clinical tests increased to 11,627.
During the company's third quarter earnings call, CEO Mark Casper highlighted a number of recent clinical and diagnostic product launches and initiatives.
The FDA-approved complementary assay "can provide insight into the survival benefit that may be achieved" with the treatment, Roche said.